We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

61 hedge funds and large institutions have $34.6M invested in Summit Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

819% more capital invested

Capital invested by funds: $3.76M → $34.6M (+$30.8M)

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

157% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 7

36% more funds holding

Funds holding: 45 → 61 (+16)

21% more call options, than puts

Call options by funds: $5.59M | Put options by funds: $4.63M

2.44% more ownership

Funds ownership: 1.59% → 4.03% (+2.4%)

Holders
61
Holders Change
+16
Holders Change %
+35.56%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
18
Reduced
7
Closed
9
Calls
$5.59M
Puts
$4.63M
Net Calls
+$952K
Net Calls Change
+$858K

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$3.64M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.21M
3
Marshall Wace
Marshall Wace
United Kingdom
+$877K
4
SPIA
Steward Partners Investment Advisory
New York
+$555K
5
AIC
AWM Investment Company
New York
+$546K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$514K
2
Morgan Stanley
Morgan Stanley
New York
-$241K
3
UBS Group
UBS Group
Switzerland
-$85.2K
4
Group One Trading
Group One Trading
Illinois
-$39.5K
5
Wells Fargo
Wells Fargo
California
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFI
26
Susquehanna Fundamental Investments
Pennsylvania
$170K +$72.9K +40,055 New
LCS
27
Levin Capital Strategies
New York
$166K – – –
HF
28
HRT Financial
New York
$163K +$69.9K +38,426 New
H
29
HoyleCohen
California
$129K – – –
TRCT
30
Tower Research Capital (TRC)
New York
$115K +$28.5K +15,689 +138%
VF
31
Virtu Financial
New York
$109K +$46.5K +25,580 New
Renaissance Technologies
32
Renaissance Technologies
New York
$99K +$42.4K +23,300 New
Man Group
33
Man Group
United Kingdom
$98.1K +$13.4K +7,373 +47%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$89.7K +$38.4K +21,111 New
IC
35
Inscription Capital
Texas
$72.3K – – –
ProShare Advisors
36
ProShare Advisors
Maryland
$70.8K -$498 -274 -2%
Simplex Trading
37
Simplex Trading
Illinois
$65K +$28.2K +15,529 New
Charles Schwab
38
Charles Schwab
California
$64.2K +$27.5K +15,112 New
Barclays
39
Barclays
United Kingdom
$58.9K +$21.4K +11,770 +563%
JP Morgan Chase
40
JP Morgan Chase
New York
$58K +$2.17K +1,190 +10%
VW
41
Vance Wealth
California
$56.5K – – –
GCP
42
GSA Capital Partners
United Kingdom
$53K +$22.7K +12,500 New
Bank of America
43
Bank of America
North Carolina
$38K +$13.2K +7,268 +432%
CG
44
Cutler Group
California
$28K +$12K +6,600 +6,600%
Wells Fargo
45
Wells Fargo
California
$24.3K -$28K -15,394 -73%
OCM
46
Osterweis Capital Management
California
$21.3K – – –
National Bank of Canada
47
National Bank of Canada
Quebec, Canada
$13.7K – – –
WAM
48
Worth Asset Management
Texas
$12.8K – – –
Group One Trading
49
Group One Trading
Illinois
$12.7K -$39.5K -21,717 -88%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$11K +$4.72K +2,593 New
1
2
3

SMMT Hedge Fund Activity: Q4 2022 in Review

61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2022, worth a combined $34.6M — up 819% from $3.76M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SMMT positions and 9 closed out — a net gain of 16 holders — while 18 added to existing stakes and 7 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.64M. The largest seller was Millennium Management, exiting entirely with an estimated $514K sold.

  • 61 institutional investors held Summit Therapeutics (SMMT) as of Q4 2022, up from 45 in Q3 2022.
  • Funds reported $34.6M of Summit Therapeutics stock for Q4 2022, up 819% quarter-over-quarter.
  • 25 funds opened new Summit Therapeutics positions in Q4 2022 and 9 closed out, a net change of +16 holders.
  • The largest Summit Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.64M added.
  • The largest Summit Therapeutics seller in Q4 2022 was Millennium Management, an estimated $514K sold.

Based on aggregated 13F filings for Q4 2022.